Guido Dalbagni, MD, FACS

Video

Meet Urologic Cancer Surgeon Guido Dalbagni

Urologic surgeon Guido Dalbagni – who cares for patients with bladder cancer, kidney cancer, penile cancer, and sarcomas – explains new treatments offered at Memorial Sloan-Kettering, which can help patients of any age maintain their quality of life.

(02:00)

I am a urologic surgeon with expertise in the treatment of urologic tumors — which include bladder, urethral, and kidney cancers. I am currently heading clinical trials at Memorial Sloan-Kettering to evaluate new therapies for the treatment of high-risk superficial bladder cancer in patients who are resistant to bacillus Calmette-Guérin (BCG) therapy, the standard treatment. I also have expertise in nerve-sparing radical cystectomy followed by bladder reconstruction. I have written a number of articles, and I am on the editorial boards of and a reviewer for several peer-reviewed journals.

Location

New York City

Appointments for New Patients

646-497-9068

Phone

646-422-4394

Clinical Expertise

Bladder Cancer; Upper Tract; Urologic Oncology; Kidney Cancer

Languages Spoken

English

Education

MD, Cairo University Faculty of Medicine (Egypt); MD, University of Parma (Italy)

Residencies

Cabrini Medical Center (New York); New York University Medical Center

Fellowships

Memorial Sloan-Kettering Cancer Center

Board Certifications

Urology

See My Colleagues in:

Department of Surgery›Urology Service

Clinical Trials Led by Guido Dalbagni

A Phase I/II Study of Everolimus and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Non-Muscle-Invasive Bladder Cancer

Clinical Trials Co-Investigated by Guido Dalbagni

A Phase I Study of a Neo-Urinary Conduit in Patients Requiring Urinary Diversion After Bladder Removal

A Phase III Study Comparing Standard versus Extended Pelvic Lymph Node Removal During Bladder Cancer Surgery

A Prospective Study of Quality of Life in Patients with Invasive Bladder Cancer

Publications by Guido Dalbagni

Dalbagni G, Russo P, Sheinfeld J, Mazumdar M, Tong W, Rabbani F, Donat MS, Herr HW, Sogani P, dePalma D, Bajorin D. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder.. J Clin Oncol. 2002; 20(15) :3193-8

Dalbagni G, Herr HW, Reuter VE. Impact of a second transurethral resection on the staging of T1 bladder cancer.. Urology 2002; 60(5) :824-825

Dalbagni G, Donat SM, Eschwege P, Herr HW, Zelefsky MJ. Results of high-dose brachytherapy (HDR-BRT), anterior pelvic exenteration and external beam radiotherapy for carcinoma of the female urethra. J Urol 2001; 166 :1759-1761

more…

Dalbagni G, Ren Z-P, Herr HW, Cordon-Cardo C, Reuter VE. Genetic alterations in TP53 in recurrent urothelial cancer: A longitudinal study. CI Cancer Res 2001; 7 :1797-2801

Dalbagni G, Genega E, Hashibe M, Zhang Z-F, Russo P, Herr HW, Reuter V. Cystectomy for Bladder Cancer: A Contemporary Series. J Urol 2001; 165 :1111-1116

Cozzi PJ, Bajorin DF, Tong W, Nguyen H, Scott J, Heston WDW, Dalbagni G. Toxicology and Pharmacokinetics of Intravesical Gemcitabine: A Preclinical Study in Dogs. CI Cancer Res 1999; 5 :2629-2637

Dalbagni G, Reschtschaffen T, Herr HW. Is Transurethral Biopsy of the Bladder Necessary After 3 Months to Evaluate Response to BCG Therapy. J Urol 1999; 162 :708-709

Dalbagni G, Zhang Z-F, Lacombe L, Herr HW. Male Urethral Carcinoma: Analysis of Treatment Outcome. Urology 1999; 53 :1126-1132

Dalbagni G, Zhang Z-F, Lacombe L, Herr HW. Female Urethral Carcinoma: Analysis of treatment outcome and a plea for a standardized management strategy. Br J Urol 1998; 82 :835-841

Visit PubMed for full listing of Guido Dalbagni journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

Related Multimedia See all »

Meet Urologic Cancer Surgeon Guido Dalbagni